Cargando…
How to account for hallucinations in the interpretation of the antidepressant effects of psychedelics: a translational framework
RATIONALE: Recent trials with psychedelics in major depressive disorder and treatment-resistant depression showed remarkable improvements in depressive symptoms that can last for up to several months after even a single administration. The lack of an appropriate placebo control group—as patients are...
Autores principales: | van den Berg, Manon, Magaraggia, Igor, Schreiber, Rudy, Hillhouse, Todd M., Porter, Joseph H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9166823/ https://www.ncbi.nlm.nih.gov/pubmed/35348806 http://dx.doi.org/10.1007/s00213-022-06106-8 |
Ejemplares similares
-
Expectancy in placebo-controlled trials of psychedelics: if so, so what?
por: Butler, Matt, et al.
Publicado: (2022) -
The neuropharmacology of sleep paralysis hallucinations: serotonin 2A activation and a novel therapeutic drug
por: Jalal, Baland
Publicado: (2018) -
Catalysts for change: the cellular neurobiology of psychedelics
por: Banks, Matthew I., et al.
Publicado: (2021) -
Hallucinations Under Psychedelics and in the Schizophrenia Spectrum: An Interdisciplinary and Multiscale Comparison
por: Leptourgos, Pantelis, et al.
Publicado: (2020) -
The socialization of hallucinations: Cultural priors, social
interactions, and contextual factors in the use of psychedelics
por: Dupuis, David
Publicado: (2021)